Your session is about to expire
← Back to Search
Monoclonal Antibodies
ZM008 Alone and With Pembrolizumab for Cancer
Phase 1
Recruiting
Research Sponsored by Zumutor Biologics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adequate renal function: Estimated creatinine clearance (CrCL) ≥30 mL/minute
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) scan
Must not have
Live vaccines reception within 30 days of enrollment
History of pneumonitis/interstitial lung disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at study completion in upto 36 months.
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called ZM008 in patients with advanced solid tumors who have already tried standard treatments or cannot tolerate them. The drug will be given alone at first and then in combination
Who is the study for?
This trial is for patients with various advanced solid tumors, like breast, lung, and prostate cancer, who have no standard treatment options left or can't tolerate them. It's not specified who can't join the trial.
What is being tested?
The study tests ZM008 alone and combined with Pembrolizumab to find safe doses in people whose cancers haven't responded to typical treatments. It's an early-stage (phase 1) dose-finding study.
What are the potential side effects?
Since it's a phase 1 trial of ZM008, specific side effects aren’t listed but may include typical reactions to new cancer drugs such as fatigue, nausea, and immune-related responses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidneys are functioning well enough (CrCL ≥30 mL/min).
Select...
My cancer can be measured on scans.
Select...
I am over 18 years old.
Select...
My cancer has specific mutations and I've tried all suitable targeted treatments without success or cannot take them due to health reasons.
Select...
I am fully active or can carry out light work.
Select...
My blood counts meet the required levels for treatment.
Select...
My cancer is advanced and cannot be cured with standard treatments.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not received any live vaccines in the last 30 days.
Select...
I have had lung inflammation or scarring before.
Select...
I have a serious health condition that is not under control.
Select...
I do not have major heart problems.
Select...
I stopped previous immunotherapy due to side effects.
Select...
I have brain metastasis that is not currently under control.
Select...
I am not currently on antibiotics for an infection.
Select...
I have another type of cancer that is currently active.
Select...
I have an autoimmune disease treated with drugs that affect my immune system.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ assessed at study completion in upto 36 months.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at study completion in upto 36 months.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Heart Rate
Change in systolic and diastolic BP
Changes in Temperature measurements.
+1 moreSecondary study objectives
Area Under the Plasma Concentration Versus Time Curve (AUC) of the biological product ZM008
Disease Control Rate
Immune Disease Control Rate
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
Dose escalation of ZM008.
Find a Location
Who is running the clinical trial?
Zumutor Biologics Inc.Lead Sponsor
Maloy Ghosh, PhDStudy ChairZumutor Biologics Inc.
Jyotsna FuloriaStudy DirectorFuloria Clinical Research Solutions LLC